SLC5A2 and diabetes mellitus: This has subsequently been confirmed to be a class effect in alternative SGLT2 inhibitor trials (Neal et al, 2017; McMurray et al, 2019), and much interest has since surrounded the use of these drugs in the management of fibrosis and HFpEF, with or without comorbid diabetes mellitus.